Bowman v. Monsanto — Patent Exhaustion Does Not Cover Replanting Progeny of Patented Seeds

Background

Monsanto developed and patented genetically modified soybean seeds — marketed as Roundup Ready — that are resistant to the herbicide glyphosate. Farmers who purchased Monsanto’s seeds signed a license agreement prohibiting them from saving and replanting seeds from one harvest for use in future seasons.

Vernon Bowman, an Indiana farmer, complied with this restriction for his primary growing season. But for a second, late-season planting — which he considered a riskier, lower-value crop — he purchased commodity soybeans from a local grain elevator rather than directly from Monsanto. He knew these commodity beans were largely Roundup Ready and would inherit the herbicide-resistance trait. He saved seeds from subsequent harvests and replanted them over eight seasons. Monsanto sued for patent infringement. Bowman argued that the patent exhaustion doctrine — which holds that a patent owner’s rights are “exhausted” upon the first authorized sale of the patented article — protected him.

The Court’s Holding

Justice Kagan, writing unanimously for the Court, held that patent exhaustion does not permit a purchaser to make new copies of a patented item, even a self-replicating one. Exhaustion applies to the specific seeds sold in an authorized transaction — it does not extend to new seeds grown from those seeds. When Bowman planted commodity soybeans and grew a new crop, he was not using the originally purchased seeds; he was creating newly infringing articles.

The Court acknowledged the unusual nature of self-replicating technology but held that creating a rule exempting it from patent protection would effectively eliminate patent rights in agricultural biotechnology. Allowing a farmer to “use” a patented seed by planting it and selling the entire resulting crop — while saving seeds for replanting — would negate the patent’s value across growing seasons.

Key Takeaways

• Patent exhaustion covers only the specific authorized sale — it does not extend to new articles created from the originally purchased item, including progeny seeds.
• Farmers who plant patented seeds and save progeny seeds for future planting infringe the patent, even if the original seeds were purchased through legitimate channels.
• The decision preserves the viability of seed patents in agricultural biotechnology and affirms Monsanto’s license model.
• The ruling left open how exhaustion applies to other self-replicating technologies (e.g., cell lines, software that makes copies of itself), with the Court cautioning that its reasoning was limited to the facts at hand.

Why It Matters

Bowman v. Monsanto resolved a high-stakes question for the agricultural biotech industry: could the patent exhaustion doctrine unravel the seed patent licensing model that underpins billions of dollars in agricultural innovation investment? The unanimous answer was no. Farmers who buy patented seeds get the right to use those seeds — but not to manufacture new ones.

The decision has implications well beyond farming. The Court’s reasoning — that exhaustion does not permit reproduction of a patented article — applies to any self-replicating technology: bacteria, cell lines, and potentially software in certain contexts. While the Court was careful to limit its holding to the facts before it, Bowman signals that innovators in biotech and other fields can rely on patent rights even when their inventions reproduce themselves.